5-O-Caffeoylshikimic acid NEW
| Price | $98 | $259 | $386 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-15 |
Product Details
| Product Name: 5-O-Caffeoylshikimic acid | CAS No.: 73263-62-4 |
| Purity: 99.82% | Supply Ability: 10g |
| Release date: 2025/07/15 |
Product Introduction
Bioactivity
| Name | 5-O-Caffeoylshikimic acid |
| Description | 5-O-Caffeoylshikimic acid shows anti-oxidative activity; it also shows anti-inflammatory activity, the underlying mechanism was associated with downregulation of nuclear factor-κB. |
| In vitro | Cytotoxic activity of saponins and phenolic compounds have been described in the literature, but no reports were found on their multidrug resistance (MDR)-modulating effects on human mdr1 gene-transfected mouse lymphoma cell line.Methylprototribestin, structurally related compounds and a mixture of 3 acetylated isomers of methylprotodioscin were investigated for antiproliferative effect and modulation of drug accumulation. RESULTS: The growth inhibitory dose (ID50) of the compounds ranged from 12.64 to 20.62 mug/ml. Methylprototribestin was the most effective resistance modifier. However, methylprotodioscin, pseudoprotodioscin, prosapogenin A of dioscin, tribestin and 5-O-Caffeoylshikimic acid showed moderate MDR reversal activity. In a checkerboard method, methyloprototribestin and the mixture of the 3 acetylated isomers enhanced the antiproliferative effects on MDR cells in combination with doxorubicin. CONCLUSION: Based on these results, methylprototribestin and the mixture of the 3 acetylated isomers can be recommended for further in vivo experiments in combination with anthracyclines in human MDR-cancer xenograft transplanted mice[1] |
| Storage | keep away from direct sunlight,store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice./Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (148.68 mM), Sonication is recommended. H2O : 20 mg/mL (59.47 mM), Sonication is recommended. |
| Keywords | TNF-α | NOSynthase | NO Synthase | Inhibitor | inhibit | ILReceptor | IL Receptor | 5-O-Caffeoylshikimic acid | 5OCaffeoylshikimic acid | 5 O Caffeoylshikimic acid |
| Inhibitors Related | Inosine pranobex | Amlexanox | L-NAME hydrochloride | Chondroitin sulfate | Mifepristone | Glucosamine | L-Arginine | Apremilast | Ethyl cinnamate | Dexamethasone | Lenalidomide | Diallyl disulfide |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Polyphenolic Natural Product Library | Traditional Chinese Medicine Monomer Library | Rare Natural Product Library | Selected Plant-Sourced Compound Library | Anti-Inflammatory Traditional Chinese Medicine Compound Library | Natural Product Library for HTS | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Heat-Clearing and Detoxifying Traditional Chinese Medicine Compound Library | Ancient Chinese Classical Formulas Compound Library | Food as Medicine Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $100.00/25KG |
VIP8Y
|
Anhui Royal Chemical Co., Ltd.
|
2024-05-22 | |
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $0.00/1G |
VIP1Y
|
Shenzhen Nexcon Pharmatechs Ltd.
|
2025-06-04 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY